Daré Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea
December 12, 2022 08:00 ET
|
Daré Bioscience, Inc.
DARE-PDM1 Utilizes Proprietary Hydrogel Technology for Vaginal Delivery of Diclofenac, a Nonsteroidal Anti-Inflammatory; Phase 1 Study Targeted for 2023 2022 Daré Portfolio Accomplishments Include:...
Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health
November 15, 2022 08:00 ET
|
Daré Bioscience, Inc.
Grant Funds Will Support Development of a Reconstitutable Vaginal Thermosetting Gel Formulation to Ultimately Serve as a Delivery Vehicle that Allows Administration of Live Biotherapeutics at the...
Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study
November 14, 2022 08:00 ET
|
Daré Bioscience, Inc.
DARE-VVA1 Demonstrated Improvement in Vaginal Cytology Parameters and Bothersome Symptoms of Vulvar and Vaginal Atrophy (VVA), Supporting Ongoing Development Investigational Therapy for Women with...
Daré Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Update
November 10, 2022 05:45 ET
|
Daré Bioscience, Inc.
September 30, 2022: $40.4 million in cash and cash equivalentsOvaprene®: IDE approval from FDA for pivotal Phase 3 study; additional study design considerations being reviewed and implemented to...
Daré Bioscience to Present at the Stifel 2022 Healthcare Conference
November 08, 2022 08:00 ET
|
Daré Bioscience, Inc.
SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and...
Daré Bioscience to Host Third Quarter 2022 Financial Results and Company Update Conference Call and Webcast on November 10, 2022
November 03, 2022 08:00 ET
|
Daré Bioscience, Inc.
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30...
Daré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete
November 01, 2022 08:00 ET
|
Daré Bioscience, Inc.
Approximately 160 to 170 Subjects in Total Are Expected to Complete the Clinical Study;Approximately 100 Subjects Have Completed All Study Assessments to Date Topline Data of Phase 2b RESPOND Study...
Daré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study
October 17, 2022 08:00 ET
|
Daré Bioscience, Inc.
Statistically Significant Results for Improvement in both the Vasomotor and the Vaginal Symptoms of Menopause DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal ring...
Daré Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive
October 10, 2022 08:00 ET
|
Daré Bioscience, Inc.
SAN DIEGO, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the U.S. Food & Drug Administration (FDA) approved...
Daré Bioscience to Participate in Two Upcoming Conferences
September 15, 2022 08:00 ET
|
Daré Bioscience, Inc.
SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and...